MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02437nam a22003497a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
210607s20212021 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
2072-6694 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.3390/cancers13071566 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
cancers13071566 [pii] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
PMC8036652 [pmc] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
33805415 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. [Review] |
| 251 ## - Source |
|---|
| Source |
Cancers. 13(7), 2021 Mar 29. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Cancers (Basel). 13(7), 2021 Mar 29. |
| 253 ## - Journal Name |
|---|
| Journal name |
Cancers |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2021 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2021 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
epublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2021-06-07 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Multi-gene assays often include UGT1A1 and, in certain instances, may report associated toxicity risks for irinotecan, belinostat, pazopanib, and nilotinib. However, guidance for incorporating UGT1A1 results into therapeutic decision-making is mostly lacking for these anticancer drugs. We summarized meta-analyses, genome-wide association studies, clinical trials, drug labels, and guidelines relating to the impact of UGT1A1 polymorphisms on irinotecan, belinostat, pazopanib, or nilotinib toxicities. For irinotecan, UGT1A1*28 was significantly associated with neutropenia and diarrhea, particularly with doses >= 180 mg/m2, supporting the use of UGT1A1 to guide irinotecan prescribing. The drug label for belinostat recommends a reduced starting dose of 750 mg/m2 for UGT1A1*28 homozygotes, though published studies supporting this recommendation are sparse. There was a correlation between UGT1A1 polymorphisms and pazopanib-induced hepatotoxicity, though further studies are needed to elucidate the role of UGT1A1-guided pazopanib dose adjustments. Limited studies have investigated the association between UGT1A1 polymorphisms and nilotinib-induced hepatotoxicity, with data currently insufficient for UGT1A1-guided nilotinib dose adjustments. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Associate Dean for Research Development |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
MedStar Health |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Swain, Sandra M |
| 790 ## - Authors |
|---|
| All authors |
Bottiglieri S, Carballido E, Cueto AD, Hicks JK, Imanirad I, Levine R, Nelson RS, Parker AS, Seligson ND, Swain SM, Tillman EM |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.3390/cancers13071566">https://dx.doi.org/10.3390/cancers13071566</a> |
| Public note |
https://dx.doi.org/10.3390/cancers13071566 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
